The Egyptian Drug Authority (EDA) has ordered a Class I recall of one batch of Appavisc HVPFS, manufactured by Chironephre International, after EDA laboratories found the batch non-conforming to specification.
Class I is the EDA’s highest recall severity. Distributors, pharmacies and health facilities must stop circulation of the batch, seize it and place it under quarantine. The recall applies only to the batch identified in the notice and not to circulation of the product generally.
| Product | Batch | Expiry | Manufacturer |
|---|---|---|---|
| Appavisc HVPFS | AVH-051-E | 31 March 2028 | Chironephre International |
The EDA said the corrective action is suspension of circulation, seizure and quarantine of the non-conforming batch. Anyone in doubt about the product is directed to contact the authority on its 15301 hotline or through its website, and complaints should be raised with the dispensing pharmacist or reported to the EDA.
Source: https://dev.edaegypt.gov.eg/media/rrbadukx/appaviscسحب.pdf
